Repeated COVID-19 Infection May Increase Long-Term Symptoms Risk

Strategic Insights -

Researchers from Yale University School of Medicine and the Centers for Disease Control and Prevention (CDC) published a study in Clinical Infectious Diseases, examining the impact of repeated SARS-CoV-2 infections on long-term clinical outcomes. The study found that repeated infection with Omicron variants may increase the risk of long-term symptoms, while the risk of severe fatigue and organ system symptoms decreased in individuals reinfected compared to those with a single infection. The analysis included data from the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) and involved 886 individuals, with 415 experiencing reinfection.

Key Takeaways:

  • The study found that repeated infection with Omicron variants may increase the risk of long-term symptoms, specifically severe fatigue and organ system symptoms.
  • Individuals who experienced reinfection had a lower risk of severe fatigue and organ system symptoms 3-6 months after their most recent infection compared to those with a single infection.
  • The analysis included 886 individuals, 415 (46.8%) of whom experienced reinfection.
  • The study analyzed outcomes for individuals who experienced their first infections during the pre-Delta, Delta, and Omicron wave periods.
  • The research concluded that repeated infection with Omicron variants may increase the risk of long-term symptoms.

Statistics:

  • The study included data from 886 individuals, with 415 experiencing reinfection (46.8%).
  • The analysis found that individuals reinfected during the Omicron wave had a 54% increased risk of reporting 3 symptoms after their most recent infection compared to those with a single infection (weighted adjusted odds ratio, 1.54 [95% confidence interval, 1.02-2.34]).
  • The odds of having severe fatigue and organ system symptoms 3-6 months after the latest infection were lower in reinfected individuals compared to those with a single infection (weighted adjusted odds ratio, 0.45 [95% confidence interval, .21-.95] and 0.51 [.32-.79], respectively).

Sources:

  • "The Effect of SARS-CoV-2 Reinfection on Long-Term Symptoms in the Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE)" (Clinical Infectious Diseases, 2025;81(3):416-426).
  • Medical Letter on the CDC & FDA (NewsRx, October 26, 2025; p 60).